The Drug Safety Executive Council and Data Sciences International Announce Collaborative Software Validation

NEEDHAM, Massachusetts and ST. PAUL, Minnesota – August, 18, 2011 – The Drug Safety Executive Council (DSEC), an industry membership run by Cambridge Healthtech Associates (CHA), and Data Sciences International (DSI), pioneers in the development of wireless implantable devices and software for collecting and analyzing physiological data in life sciences, today announced a new consortium project which aims to reduce the time and financial cost of validating GLP data acquisition and analysis systems.

CHA is organizing a consortium of pharmaceutical companies and contract research organizations (CROs) to collaboratively validate Ponemah 5.0. The consortium will leverage insights and opinions from multiple companies and enable a cooperative approach to validating Ponemah 5.0 and potentially future versions of the software.

Ponemah is DSI’s industry leading data acquisition and analysis system, with software consisting of a library of pre-programmed, validated analysis modules. The Ponemah suite also offers add-on modules for ECG analysis, study data management, pressure volume loop analysis and reporting.

“Our experience with customers indicates that a significant amount of GLP software validation is duplicated within and across companies. By bringing customers together to validate Ponemah 5.0 we hope to streamline the process, reducing the time and cost of validation,” said R. Dustan Sarazan, Chief Scientific Officer and Vice President of Strategic Planning at DSI.

“We are excited to bring our expertise of organizing consortia within life sciences, said Dr. Ernie Bush, Vice President of Collaborative Projects at CHA, “This collaborative approach will greatly reduce the burden of software validation and allow pharmaceutical companies and CROs to focus on providing safer and cost effective medicines.”

About Cambridge Healthtech Associates and the Drug Safety Executive Council
CHA is the leading organizer of consortia in life sciences. CHA reduces the costs of R&D by bringing companies together to work cooperatively. The Technology Evaluation Consortium determines the scientific utility of predictive safety technologies by leveraging the expertise of biopharmaceutical companies. CHA also manages DSEC, an online, peer membership of over 2,000 drug safety leaders. Learn more at www.chacorporate.com and
www.drugsafetycouncil.org. CHA is wholly-owned subsidiary of Cambridge Healthtech Institute (CHI).

**About Data Sciences International (DSI)**

Founded in 1984, DSI is a pioneering biomedical research technology company focused primarily on nonclinical systems physiology and pharmacology. A complete solution provider, DSI offers instrumentation, software and services that facilitate accelerated, well informed, drug discovery and development decisions. Learn more at [www.datasci.com](http://www.datasci.com).

### CONTACT:

**Drug Safety Executive Council (DSEC)**

Contact: Alison Serrano  
Tel: + 1 (781) 972-5482  
Email: aserrano@drugsafetycouncil.org

**Data Sciences International (DSI)**

Contact: Dave Johnson  
Tel: +1 (651) 414-5444  
Email: djohnson@datasci.com